A phase II, randomized, double-blind, placebo controlled trial to evaluate the antiviral activity, safety, and pharmacokinetics of novartis EYU688 against dengue virus 2 infection in a controlled…
Ended Awarded Last action
- Contract number
- 75N93023F00004
- Awardee
-
The Johns Hopkins University UEI FTMTDMBR29C7
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,617,504
Award facts
- Contract value 100% obligated
- $4,617,504.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Place of performance
- Baltimore, MD 21205, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $1,198,868 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Terminate for Convenience | $0 | |
| Terminate for Convenience | $0 | |
| Definitize Change Order | $321,765 | |
| Original award | $3,096,871 |
About this award
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $4.6M delivery order contract to The Johns Hopkins University to conduct a Phase II randomized, double-blind, placebo-controlled clinical trial evaluating the antiviral activity, safety, and pharmacokinetics of Novartis EYU688 against dengue virus 2 infection using a controlled human infection model with healthy adult participants. The work will be performed in Baltimore, Maryland, with an ultimate completion date of July 22, 2026. This contract carries no set-aside designation and operates under a cost, no fee pricing structure, indicating reimbursement of allowable costs without profit margin.
This contract supports NIAID's mission to develop and evaluate novel therapeutic interventions for infectious diseases. Johns Hopkins University, a leading research institution with extensive experience in biomedical research and infectious disease investigations, is well-positioned to execute the sophisticated clinical research requirements of this dengue virus therapeutic evaluation. The controlled human infection model approach enables accelerated assessment of drug efficacy and safety profile in a highly controlled setting, advancing the development of potential treatment options for dengue, a significant public health concern.
Description
A phase II, randomized, double-blind, placebo controlled trial to evaluate the antiviral activity, safety, and pharmacokinetics of novartis EYU688 against dengue virus 2 infection in a controlled human infection model in healthy adult participants
Quick answers
Who was awarded contract 75N93023F00004?
75N93023F00004 was awarded to The Johns Hopkins University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 23, 2023.
How much is contract 75N93023F00004 worth?
The government has obligated $4,617,504 on 75N93023F00004.
Is contract 75N93023F00004 an order under another contract?
Yes. 75N93023F00004 is a delivery order under 75N93019D00031, an indefinite delivery contract.
Was contract 75N93023F00004 competed?
The extent of competition for 75N93023F00004 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award